Per2 Mutation Recapitulates the Vascular Phenotype of Diabetes in the Retina and Bone Marrow
- Ashay D. Bhatwadekar1,
- Yuanqing Yan1,
- Xiaoping Qi2,
- Jeffrey S. Thinschmidt1,
- Matthew B. Neu1,
- Sergio Li Calzi1,
- Lynn C. Shaw1,
- James M. Dominiguez1,
- Julia V. Busik3,
- Choogon Lee4,
- Michael E. Boulton2 and
- Maria B. Grant1⇓
- 1Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida
- 2Department of Anatomy and Cell Biology, University of Florida, Gainesville, Florida
- 3Department of Physiology, Michigan State University, East Lansing, Michigan
- 4Biomedical Sciences Department, Florida State University, Tallahassee, Florida
- Corresponding author: Maria B. Grant, grantma@.ufl.edu.
In this study, we assessed whether Per2 clock gene–mutant mice exhibit a vascular phenotype similar to diabetes. Per2 (B6.129-Per2tm1Drw/J) or wild-type control mice 4 and 12 months of age were used. To evaluate diabetes-like phenotype in Per2 mutant mice, retina was quantified for mRNA expression, and degree of diabetic retinopathy was evaluated. Bone marrow neuropathy was studied by staining femurs for tyrosine hydroxylase (TH) and neurofilament 200 (NF-200). The rate of proliferation and quantification of bone marrow progenitor cells (BMPCs) was performed, and a threefold decrease in proliferation and 50% reduction in nitric oxide levels were observed in Per2 mutant mice. TH-positive nerve processes and NF-200 staining were reduced in Per2 mutant mice. Both retinal protein and mRNA expression of endothelial nitric oxide synthase were decreased by twofold. Other endothelial function genes (VEGFR2, VEGFR1) were downregulated (1.5–2-fold) in Per2 mutant retinas, whereas there was an upregulation of profibrotic pathway mediated by transforming growth factor-β1. Our studies suggest that Per2 mutant mice recapitulate key aspects of diabetes without the metabolic abnormalities, including retinal vascular damage, neuronal loss in the bone marrow, and diminished BMPC function.
The endogenous circadian system drives the daily timing of many physiological and behavioral processes. The circadian oscillations not only are consequences of light perception, but also are generated by endogenous circadian clocks that can adapt the physiology of an organism to its needs in an anticipatory manner. Acute pathologic events exhibit diurnal patterns; the incidence of acute myocardial infarction, myocardial ischemia, cardiac arrest, ventricular tachycardia, and sudden death caused by heart failure all vary according to the time of day (1). Circadian clocks form a series of intrinsic self-sustained transcriptional and translational feedback loops that persist in tissue even when isolated in vitro or cultured (2), and about 5–10% of transcriptome is under circadian control in the liver, heart, suprachiasmatic nucleus, aorta (3), and vertebrate retina. The predominant expression of clock genes in mammalian retina are observed in dopaminergic cells of the inner nuclear layer and in cells of the ganglion cell layer (4).
Bone marrow progenitor cells (BMPCs) show a typical diurnal pattern of release, with levels peaking during rest, while at nadir in the active phase both in humans (5) and in rodents (6), which is altered in diabetes (7–9). Reduced neuronal input to the bone marrow is deemed responsible for the dysfunctional release of these cells. Because this bone marrow neuropathy results in a reduced release of reparative progenitor cells in the circulation, we postulate that this defect in BMPC release contributes to the development of the vasodegenerative phase of diabetic retinopathy. Diabetes not only induces a circadian defect in BMPC release, but also severely compromises the reparative potential of BMPCs through proliferative, migratory defects (10) and by creating a hostile environment that prevents proper repair as a result of advanced glycation modification of the basement membrane (11). Reduced bioavailability of nitric oxide (NO) is one of the pathogenic features of dysfunction in diabetic BMPCs (12).
Per genes are at the core of the circadian clock mechanism, and phosphorylation kinetics of PER proteins dictate period length of the circadian clock. PER2 proteins undergo posttranscriptional modification, and mutations in Per2 can abolish normal phosphorylation, leading to familial advanced sleep phase syndrome (13). Per2 is spontaneously expressed in the retina immediately after birth, mainly in the inner part of the neuroblastic retina, and from postnatal day 1, Per2 gradually develops into the inner nuclear layer of mature eye. Homozygous mutant mice for Per2 show aberrant gene products for Per2 and do not produce any functional PER2 proteins. Several transcript forms of the mPer2 allele could, if translated, generate a truncated form of PER2 proteins lacking 108 amino acids and devoid of any activity. Mutations in Per2 have been documented in cancer (14), increased alcohol consumption (15), altered mood behavior (16), shortened life span, and endothelial dysfunction (17).
Endothelial dysfunction is central to the underlying pathology of diabetic vascular diseases along with inadequate contribution by BMPCs to repair injured endothelium. Several studies reported the importance of Per2 in normal endothelial function (17,18), but how Per2 mutation influences retinal vascular function, bone marrow innervation, and the reparative ability of BMPCs have not been explored.
RESEARCH DESIGN AND METHODS
All animal studies were approved by the institutional animal care and use committee and conducted in accordance with National Institutes of Health guiding principles in the care and use of animals and the Association for Research in Vision and Ophthalmology ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Wild-type or Per2 mutant (B6.129-Per2tm1Drw/J) mice 4–12 months of age were maintained in a colony at animal care facilities of Florida State University. At study termination, the animals were killed by an overdose of ketamine 14 mg/kg and xylazine 30 mg/kg.
Trypsin digestion of mouse retina.
Trypsin digestion of retina was performed as described previously (19), and the number of acellular capillaries per square millimeter of retina were quantified.
Endothelial nitric oxide synthase staining of mouse retina.
Retinal trypsin digests were stained with anti-endothelial nitric oxide synthase (eNOS) antibodies (Sigma-Aldrich, St. Louis, MO) followed by staining with fluorescein isothiocyanate (FITC)-conjugated secondary antibodies (Invitrogen, Carlsbad, CA).
Retinal permeability and tight junction staining.
Retinal permeability was assessed after tail vein injections of FITC-albumin 20 mg/kg (Sigma-Aldrich), as explained previously (20). In parallel experiments, flat-mounted retinas were stained for claudin-5 (Abcam, Cambridge, MA) and vascular endothelial (VE)-cadherin (Cell Signaling Technology, Inc., Danvers, MA). Digital images of flat-mounted retinas were obtained using a confocal microscope (Olympus DSU-Olympus IX81, Olympus America, Inc., Center Valley, PA).
Quantitative RT-PCR for mRNA expression.
Equal amounts of total retinal RNA were reverse transcribed using iScript (Bio-Rad, Hercules, CA). Gene-specific primers for eNOS, inducible nitric oxide synthase (iNOS), vascular endothelial growth factor (VEGF) and receptors VEGFR1 and VEGFR2, transforming growth factor-β1 (TGF-β1), connective tissue growth factor (CTGF), plasminogen activator inhibitor 1 (PAI-1), and ID-1 (Applied Biosystems, Foster City, CA) were used to run quantitative RT-PCR. All genes were normalized to mouse TATA-binding protein.
Quantification of BMPCs.
BMPCs were quantified as lin– sca1+ c-Kit+ (LSK) cells using flow cytometry. Lin cells were stained with biotin mouse lineage panel followed by FITC-streptavidin (eBioscience, San Diego, CA), whereas sca1 and c-kit cells were stained using PE-rat anti-mouse Ly-6A/E and APC rat anti-mouse CD117 (BD Pharmingen), respectively.
Quantification of NO by DAF-FM fluorescence.
NO was quantified from LSK cells as described previously (21).
Colony-forming assay for mouse hematopoietic stem cells.
Bone marrow mononuclear cells (1 × 104) were plated for assay using MethoCult (STEMCELL Technologies Inc.), and numbers of colonies were enumerated at 7–10 days.
Tyrosine hydroxylase and neurofilament 200 staining of bone marrow.
Tyrosine hydroxylase (TH) and neurofilament 200 (NF-200) staining of femurs was performed as described previously (7).
Assessment of vascularity in sciatic nerves.
Sciatic nerve vascularity was assessed by in situ staining with rhodamine-conjugated Bandeiraea simplicifolia (BS)-1 isolectin (Vector Laboratories), and the number of vessels were quantified by transverse sectioning.
All results are expressed as mean ± SEM. The comparisons for more than two groups were analyzed using one-way ANOVA followed by Student-Newman-Keuls post hoc analysis. Unpaired two-tailed Student t test was used for two-group comparisons, whereas data for glucose tolerance tests were analyzed using two-way ANOVA followed by Bonferroni test. All the statistical tests were performed using GraphPad (La Jolla, CA) software. P < 0.05 was considered statistically significant.
Per2 mutant mice are normoglycemic.
To determine whether Per2 mutation alters mouse metabolism, we measured HbA1c and blood glucose levels and body weight of wild-type and Per2 mutant mice. There was no significant difference in blood glucose levels at either age; however, in 12-month-old mice, there was an insignificant increase (wild type 4.1 ± 0.081%, Per2 mutant 4.6 ± 0.088%) in HbA1c levels in the Per2 mutant mice (Supplementary Table 1).
To assess the possibility of glucose intolerance in the Per2 mutant mice, we performed glucose tolerance tests on 12-month-old mice. After injection of glucose 2 g/kg, plasma glucose levels showed a sharp increase in both wild-type and Per2 mutant mice. Both groups showed recovery in blood glucose 1 h postinjection; however, Per2 mutant mice showed a significant decrease in blood glucose level (P < 0.01). Moreover, the recovery after glucose challenge was better in Per2 mutant mice at 2 h (Supplementary Fig. 1).
Decrease in eNOS expression in the retina of Per2 mutant mice.
Retinal digests prepared from Per2 mutant animals showed less eNOS immunoreactivity (Fig. 1A). To study whether the decrease in protein expression of eNOS correlated with gene expression, eNOS mRNA expression was studied. A twofold decrease (P < 0.05) in eNOS mRNA was observed in Per2 mutant animals at both ages (Fig. 1B). At 12 months, the eNOS decrease was accompanied by a dramatic increase in iNOS expression (P < 0.05) in Per2 mutant mice, whereas wild-type mice showed a decrease in iNOS mRNA expression at 12 versus 4 months of age (Fig. 1C).
Per2 mutant mice show an increase in acellular capillaries.
Trypsin digestion of retinas was performed to assess whether Per2 mutation results in retinal endothelial damage. Quantification of acellular capillaries in the retina provides a direct measure of degree of retinal vascular injury. Per2 mutant mice showed a 40% increase (P < 0.05) in the number of acellular capillaries, suggesting an accelerated progression of vascular dysfunction in Per2 mutant retinas (Fig. 2A and B).
Increase in retinal permeability in Per2 mutant mice.
To determine whether an increase in acellular capillary numbers in Per2 mutant mice is also accompanied by alteration in vascular permeability, in vivo permeability assay was performed. As shown in Fig. 3A, we observed a profound increase in retinal vascular leakage of FITC-albumin in Per2 mutant retinas compared with negligible leakage of albumin in wild-type retinas.
To evaluate blood-retinal barrier integrity, immunohistochemical analysis in parallel experiments of retinal flat mounts for claudin-5 and VE-cadherin was performed. Wild-type retinas showed clearly demarcated lateral membranes of endothelial cells, exhibiting integrity of junctional complexes for both claudin-5 and VE-cadherin. In contrast, Per2 mutant retinas showed significant attenuation of claudin-5 expression and dissociation of cadherin junctions (Fig. 3B).
Increased expression of TGF-β1 and downstream mediators of TGF-β1 action in Per2 mutant retina.
To further explore the mechanism of the vascular dysfunction observed, we examined established markers of retinal vascular pathology. As shown in Fig. 4A and B, we observed a 1.5- and 2-fold decrease in VEGFR2 and VEGFR1 expression, respectively, in Per2 mutant retinas at 12 months of age (P < 0.001). However, there was no change in VEGF expression in either age group (Fig. 4C), and Per2 mutant retinas formed similar numbers of branch points and possessed equivalent vessel length (data not shown) compared with wild-type mouse retinas.
TGF-β1 and its downstream effectors, including CTGF, PAI-1, ID-1, and fibronectin (FN), have been implicated in both microvascular and macrovascular disease. Per2 mutant mice showed an increase in TGF-β1 mRNA levels in retina at both 4 and 12 months of age, but this was not statistically significant (Fig. 4D). PAI-1, the major target gene of TGF-β1, was increased twofold (P < 0.05) at 4 months of age in the Per2 mutant mice (Fig. 4E). ID-1, a critical mediator of TGF-β1 and cell differentiation, was increased twofold (P < 0.05) in 12-month-old Per2 mutant mice (Fig. 4F). CTGF, an important downstream mediator of profibrotic effects of TGF-β1, has been implicated in vascular dysfunction (22). A 2.5–3-fold increase in CTGF expression was observed in Per2 mutant retinas (P < 0.05) (Fig. 4G). At 4 months of age, retinas of Per2 mutant mice showed a 2.5-fold increase (P < 0.05) (Fig. 4H) in FN expression, suggesting a potential role of extracellular matrix proteins in the progression of retinal vascular dysfunction; however, no difference was observed at 12 months of age.
Dysfunction in BMPC release from bone marrow in Per2 mutant mice.
To study the contribution of BMPCs in developing retinal vascular dysfunction, the numbers of LSK cells were quantified in bone marrow using flow cytometry. The bone marrow was flushed; erythrocytes were lysed; and after washing with PBS, the mononuclear cells were incubated with sca1 and c-kit antibodies. Figure 5A shows the hierarchy of flow cytometry gating. The LSK cell population was gated based on low side scatter (gate 1); typically, blood cells smaller in size with a single nucleus (e.g., monocytes, lymphocytes) and BMPCs can be efficiently gated using this strategy. By using successive gating, positively stained sca1+ cells were subsequently gated for the lin– and sca1+ populations (gate 2). This population was further separated for sca1+ and c-kit+ populations to determine the LSK+ population. Quantification of the LSK population showed that 4-month-old Per2 mutant mice showed twofold more cells (Fig. 5B) (P < 0.05) within the bone marrow, suggesting an inability of Per2 mutant BMPCs to egress from the bone marrow. There was a dramatic decrease (∼200 times) in number of BMPCs in both wild-type and Per2 mutant mice at 12 months of age, which may be attributed to aging and progressive bone marrow exhaustion (Fig. 5B).
BMPCs of Per2 mutant mice show decreased colony formation and NO levels.
Methylcellulose colony-forming assays provide a direct estimate of BMPC proliferative potential. To determine whether bone marrow cells from Per2 mutant mice possess impaired proliferation, mononuclear cells were propagated on methylcellulose cultures, and the number of colonies was quantified at 7 days. Wild-type animals exhibited robust colony formation (Fig. 6A), whereas a dramatic decrease in number of colonies of Per2 mutant animals was observed. Quantification of number of colonies showed a threefold decrease (P < 0.05) in Per2 mutant mice at both ages (Fig. 6B). To further characterize dysfunction in BMPCs, NO concentration in BMPCs was quantified using DAF-FM fluorescence. BMPCs obtained from Per2 mutant mice showed a 1.5-fold decrease in NO levels (P < 0.05) (Fig. 6C).
Bone marrow neuropathy in Per2 mutant mice.
TH is a rate-limiting step in catecholamine synthesis, which directly contributes to the release of BMPCs. To determine the number of TH-positive nerve fibers, femurs were sectioned, and immunohistochemical staining for TH was performed. Bone marrow of both wild-type and Per2 mutant mice showed positive staining of TH nerve fibers adjacent to blood vessels (Fig. 7A); however, 4-month-old Per2 mutant mice showed a dramatic increase in TH-positive nerve processes (P < 0.05) compared with wild-type controls. In contrast, by 12 months of age, a fivefold decrease (P < 0.05) in TH staining in the Per2 mutant animals was observed compared with wild-type controls (Fig. 7B). These fluctuations in TH staining suggest modulation of noradrenergic neurons. To assess whether these changes were associated with a change in total innervations, NF-200 staining was performed. Figure 7C shows fewer NF-200-positive nerve processes in Per2 mutant animals. Quantification of NF-200 nerve processes showed a 20 and 30% decrease (P < 0.05) in 4- and 12-month-old Per2 mutant animals, respectively, compared with age-matched wild-type controls (Fig. 7D). To determine whether neural vascularity was mediating the bone marrow changes, we studied the vasa nervorum of sciatic nerves using an injection of rhodamine-conjugated BS-1 lectin before the animals were killed. Per2 mutant mice showed a reduction in the number of vessels (Fig. 8A). Quantification of neural vascularity showed an ∼25% decrease (P < 0.05) in number of vessels in Per2 mutant mice (Fig. 8B).
Alterations in circadian rhythm are associated with several pathological conditions, including sleep disorders, cardiovascular diseases, and metabolic syndrome. The Per2 clock gene plays a central role in resetting the clock, and mutations in Per2 have been associated with endothelial dysfunction, limb ischemia, and early vascular senescence. Diabetic animals show altered circadian rhythm, with phase advancement resulting in contractile dysfunction (23). Clock and Bmal-1 pancreatic conditional knockout mice show hypoinsulinemia and develop type 1 diabetes (24). Previously, we reported that diabetes results in circadian dysregulation of BMPC release and a decrease in mRNA expression for Per2 in these cells and in retina (7).
In the present study, we show that Per2 mutant mice exhibit progressive retinal vascular dysfunction with an increase in acellular capillaries and retinal permeability, reduced eNOS expression, and upregulation of profibrotic genes. Additionally, Per2 mutant retinas show dissociation of tight junctions and adherens junctional integrity. These retinal changes are accompanied by bone marrow neuropathy with increased numbers of BMPCs retained within the bone marrow, suggesting reduced release of these cells into the circulation similar to what we observed in both type 1 and type 2 diabetic rats. However, the Per2 mutant animals show blood glucose and HbA1c levels similar to wild-type mice. Previous studies indicated that Per2 mutant mice exhibit low blood pressure and normal serum lipid levels. More importantly, Per2 mutant mice possess faster glucose clearance than wild-type animals (25,26). Consistent with previous reports, the present glucose tolerance test indicates faster clearance and recovery of blood glucose in 12-month-old Per2 mutant mice compared with wild-type controls. This finding indicates that the dysfunction associated with Per2 mutant mice is not a result of elevated glucose levels, lipid levels, or blood pressure but, rather, is directly linked to loss of Per2. Per2 is an important component of the glucocorticoid regulatory pathway, and disruption of glucocorticoid regulation and leptin regulation may be partly responsible for the enhanced glucose sensitivity observed in the Per2 mutant mice (26).
We also observed a decrease in retinal eNOS expression in Per2 mutant mice similar to that found in diabetes (27). Diabetes-associated deficiency in endothelium-derived NO coupled with activation of iNOS can generate large amounts of highly reactive oxygen species. Increased expression of iNOS has been reported in the retinas of both humans (28) and experimental animals (29). Furthermore, we previously showed that eNOS knockout mice made diabetic exhibit an acceleration of diabetic retinopathy (30) characterized by increased retinal vessel leakage, gliosis, numbers of acellular retinal capillaries, and basement membrane thickening of retinal capillaries. Functional loss of Per2 impairs endothelial function in mouse aortas and results in reduced NO production, reduced expression of the vasodilatory prostaglandin PGI (2), and increased release of cyclooxygenase (COX)-1; however, COX-2 expression was undetected (17). Although both COX-1 and COX-2 have been ubiquitously identified on ocular tissues, such as amacrine cells, ganglion cells, horizontal cells, microglia, and Müller cells (31), several reports suggested that COX-2 is the predominant mediator of vascular dysfunction acting through increasing VEGF production (32,33). However, we did not see any change in expression of retinal VEGF in Per2 mutant mice, suggesting a lack of involvement of the COX pathway in retinal vascular dysfunction.
TGF-β and its downstream effectors are implicated in the pathogenesis of diabetic retinal vascular dysfunction. In the present study, Per2 mutant retinas exhibited a dramatic increase in expressions of PAI-1 and FN, suggesting the predominant role of extracellular matrix alterations in pathogenesis of vascular dysfunction in these animals. Expression of CTGF, an important downstream mediator of profibrotic effects of TGF-β, is increased early on in the retinas of diabetic mice (34). Retinal mRNA data obtained in the present study support this notion. Moreover, we speculate that CTGF may be one of the predominant mediators of vascular dysfunction in Per2 mutant retinas. Loss of Per2 results in activation of β-catenin (35), an essential effector of the Wnt signaling pathway that is also involved in increasing CTGF expression (36) in the diabetic retina (37). Although the precise source of CTGF in the retina is not clear from the present study, previous reports showed that profibrotic factors involved in basement membrane thickening of retinal capillaries in diabetes are mainly expressed in pericytes (38), suggesting that future studies need to evaluate pericytes in Per2 mutant mice.
Of note, a significant decrease in VEGFR1 and VEGFR2 mRNA expression occurred at 12 months of age in Per2 mutant retinas; however, the total number and branching of retinal vessels was not different in these mice compared with controls. The increase in mRNA expression of VEGFR1 and VEGFR2 may reflect an age-associated capillary enlargement (39). The mechanism responsible for VEGF and VEGF receptor modulation of angiogenesis is complex. VEGFR1 regulates angiogenesis through ligand trapping or receptor heterodimerization, whereas VEGFR2 stimulates a variety of pathways controlling endothelial growth, differentiation, migration, and tubulogenesis (40). Although VEGF expression is increased in retinas of diabetic rats (41), we did not see any change in VEGF mRNA expression at either age in the Per2 mutant mice. Thus, taken together, the present study suggests that morphologically and metabolically, Per2 mutant mice are similar to wild-type mice wherein the predominant mechanism in the development of acellular capillaries involves reduced eNOS expression with a concomitant increase in proinflammatory and profibrotic markers promoting extracellular matrix thickening.
The present data indicate that the inability of BMPCs to enter the circulation can contribute to vascular dysfunction in Per2 mutant mice. Moreover, we observed a reduction in proliferative potential of BMPCs from Per2 mutant mice. This finding agrees with a typical phenotype of type 2 diabetes in a previous report, which suggested that bone marrow neuropathy results in altered release and proliferation of BMPCs (7). Orlandi et al. (42) reported that long-term diabetes specifically reduces long-term repopulating BMPCs and their proliferative potential. We also observed a similar decrease in numbers of BMPCs and colony-forming response of BMPC obtained from type 1 diabetic mice (Hazra et al. ). We observed a >94% decline of BMPCs after 12 months of diabetes. Precisely how Per2 mutation controls cell proliferation is intriguing. Downregulation of Per2 in cancer cell lines increases β-catenin protein levels and the β-catenin target protein cyclin D, accelerating cancer cell proliferation (35). Per2 mutation in endothelial cells is associated with upregulation of Akt signaling and phosphoinositide-dependent kinase-1 (PDK-1) (44). Activation of Akt/PDK-1 inactivates and phosphorylates forkhead box O (FOXO) proteins (45), which are critical in maintaining long-term repopulating of BMPC because of their ability to regulate oxidative stress (46). We believe that the decrease in FOXO levels after chronic activation of Akt is a possible mechanism for the decreased proliferation of BMPCs we observed. However, further studies are necessary to delineate the exact mechanism. We also observed a reduction in NO levels (the critical regulator of cell migration) in BMPCs isolated from the Per2 mutant mice similar to that in BMPCs isolated from diabetic mice (12). Thus, we believe that the cumulative dysfunction of proliferation, migration, and release of BMPCs can severely compromise vascular repair and may be responsible for the retinal vascular pathology we observed in Per2 mutant mice.
The bone marrow microenvironment exerts a selective inhibitory role on adherent progenitors, controlling their release into the circulation while maintaining their proliferative potential in bone marrow. Bone marrow nerve fibers run along vessels within bone marrow parenchyma (47). Neurotransmitters released by the sympathetic nervous system regulate retention and release of BMPCs. However, we did not see any change in retinal expression of TH or NF-200 (Supplementary Figs. 2 and 3), which suggests that bone marrow neuropathy plays a key role in vascular dysfunction in Per2 mutant mice. TH, the rate-limiting step in norepinephrine synthesis, is reported to be decreased in diabetes (7); similarly, we show that Per2 mutant mice exhibit a decrease in TH nerve fibers at 12 months of age. However, much to our surprise, there was a dramatic increase in TH activity in 4-month-old animals. This may result from inhibition of monoamine oxidase, which has also been observed in Per2 mutant mice (16), and suggests, perhaps, that we are observing a compensation in response to an overall decrease in the number of nerve fibers.
Diabetic neuropathy is caused by both imbalances in neuron metabolism and impaired nerve blood flow. Maintenance of an adequate supply of blood through the vasa nervorum is essential to prevent neuropathy (48). The sciatic nerve of diabetic mice possesses reduced motor and sensory nerve conduction velocities, blood flow, and capillary density (49). We observed a similar decrease in capillary density in sciatic nerves of Per2 mutant mice, which may be a result of a reduction of NO levels in sciatic nerve and vasa vasorum, leading to early vascular senescence and BMPC dysfunction as reported previously (44).
While acknowledging that mutation of retinal Per2 may also have a profound effect on retinal vascular dysfunction, the present study suggests that bone marrow neuropathy is linked to retinopathy in Per2 mutant mice. First, the decrease in neural vascularity of Per2 mutant mice contributes to reduced sympathetic neurotransmission. Second, the loss of neurotrophic support may lead to changes in the bone marrow microenvironment, resulting in BMPCs with reduced proliferative potential as well as reduced release into the circulation, limiting their participation in vascular repair. Finally, together with reduced eNOS and hyperactive profibrotic TGF-β1, this retinal vasculature and bone marrow pathology can lead to the development of acellular capillaries as a result of both endothelial dysfunction and reduced endothelial repair.
This work was supported by an American Heart Association Post-Doctoral Award and a Thomas H. Maren Junior Investigator award to A.D.B. and National Institutes of Health Grants EY-018358 to M.E.B. and EY-007739, EY-012601, U01-HL-087366, and DK-090730 to M.B.G. M.B.N. is supported by the UF-HHMI Science for Life program.
No potential conflicts of interest relevant to this article were reported.
The funder played no role in the conduct of the study, collection of data, management of the study, analysis of data, interpretation of data, or preparation of the manuscript.
A.D.B. conducted experiments and wrote the manuscript. Y.Y., X.Q., J.S.T., M.B.N., S.L.C., L.C.S., and J.M.D. helped with experiments. J.V.B., C.L., and M.E.B. reviewed and edited the manuscript. M.B.G. wrote the manuscript and helped with discussion and editing. A.D.B. and M.B.G. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
The authors thank Marda Jorgensen, McKnight Brain Institute, University of Florida, Gainesville, Florida, for technical assistance.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0172/-/DC1.
See accompanying commentary, p. 29.
- Received February 17, 2012.
- Accepted July 16, 2012.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.